Zheng Qiao

Zheng Qiao

Auto-generated profile, based on publicly available information

Zheng Qiao

State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Science Advances
Verified
Journal Article
Open access
NLNing Liu
Ning Liu
JPJianqiu Pei
Jianqiu Pei
YXYifan Xie
Yifan Xie
HXHe Xuan
He Xuan
NJNan Jiang
Nan Jiang
YNYu Nie
Yu Nie
The adult mammalian heart has limited regenerative capacity due to the low proliferative ability of cardiomyocytes, whereas embryonic cardiomyocytes exhibit robust proliferative potential. Using single-cell RNA sequencing of embryonic hearts, we identified prothymosin α (PTMA) as a key factor driving cardiomyocyte proliferation. Overexpression of PTMA in primary mouse and rat cardiomyocytes significantly promoted cardiomyocyte proliferation and similarly enhanced proliferation in human iPSC–derived cardiomyocytes. Conditional knockout of Ptma in cardiomyocytes impaired neonatal heart regeneration. AAV9-mediated overexpression of Ptma extended the neonatal proliferative window and showed therapeutic promise for enhancing adult heart regeneration. Mechanistically, PTMA interacted with MBD3, inhibiting its deacetylation activity within the MBD3/HDAC1 NuRD complex. This inhibition increased STAT3 acetylation, which positively regulated STAT3 phosphorylation and activation of its target genes. These findings establish PTMA as a critical regulator of heart regeneration and suggest its potential as a therapeutic target for ischemic myocardial injury.

22 July 2023 in Phytomedicine
Verified
Journal Article
Closed access
LDLi-Xia Du
Li-Xia Du
JZJian-Yu Zhu
Jian-Yu Zhu
TYTing Yi
Ting Yi
YYYa-Chen Yang
Ya-Chen Yang
ZQZheng Qiao
Zheng Qiao
WMWenli Mi
Wenli Mi

7 January 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
CSChenxi Song
Chenxi Song
ZQZheng Qiao
Zheng Qiao
JCJiaxi Cheng
Jiaxi Cheng
YZYuze Zhang
Yuze Zhang
WLWeida Liu
Weida Liu
KDKe-Fei Dou
Ke-Fei Dou
Background: The optimal definition and risk stratification approach to identify high‐risk patients with prediabetes and stable coronary heart disease has not been well studied to date. The objective of the current study is to compare the prognostic value of different definitions of prediabetes, and to explore the role of “very‐high‐risk” (VHR) criteria according to the 2018 American Heart Association/American College of Cardiology cholesterol guideline in the risk stratification of patients with prediabetes and stable coronary heart disease. Methods and Results: This prospective large‐cohort study enrolled a total of 7930 patients with stable coronary heart disease. Prediabetes was defined according to various guidelines and further classified on the basis of the VHR criteria according to the 2018 American Heart Association/American College of Cardiology guideline. The primary end point was major adverse cardiovascular events (MACEs), which was defined as the composite end point of cardiac death, nonfatal acute myocardial infarction, and stroke. During a median of 3 years’ follow‐up, a total of 256 MACEs occurred. Prediabetes defined according to the World Health Organization/International Expert Committee criteria was associated with significant increased MACE risk compared with normoglycemia (adjusted hazard ratio [HR], 1.484 [95% CI, 1.139–1.935]; P =0.0035). The VHR group was associated with increased MACE risk compared with the non‐VHR group (adjusted HR, 1.783 [95% CI, 1.344–2.366], P <0.0001). The VHR criteria played an important role in risk stratification, and prediabetes combined with VHR criteria was associated with higher MACE risk regardless of the prediabetes definition. Conclusions: Our findings suggested the potential use of the World Health Organization/International Expert Committee definition and VHR criteria in risk stratification of patients with prediabetes and stable coronary heart disease.